Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in active idiopathic inflammatory myopathy
CTR20243345Phase 3Active
- Sponsor
- argenx
- Start
- Dec 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of efgartigimod alfa in Autoimmune Myopathies, sponsored by argenx. Started Dec 2024; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on CTR20243345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243345.